It is sad to see pets die of something easily preventable. It's even worse knowing that the owner was misinformed or misled ...

LEVI-04, a Novel Neurotrophin-3 Inhibitor, Substantially Improves Pain and Function in People with Knee Osteoarthritis: a Randomised Controlled Phase II Trial. Authors: Conaghan, Philip G; Guermazi, ...

Positive IND-enabling data on MP0712 targeting DLL3, the most advanced Radio-DARPin program in co-development with Orano Med, entering clinical development in 2025 First preclinical data of novel ...

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission ...

Elevation Oncology, Inc. , an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet ...

Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional ...

Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the presentation of new preclinical data for its lead drug ...

Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) ...

Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it will present preclinical data of FL-501 in a poster ...

What if business leaders approached strategy the way scientists design gene delivery vectors? In biotechnology, precision, ...

All posters will be available on the ‘Posters and Publications’ page of Cogent’s website. New Leadership Appointments Cogent also announced today that Ray Frost has joined Cogent as Senior Vice ...